An inducible and cell specific transgenic mouse model to study the HIV-1 antisense protein ASP
An inducible and cell specific transgenic mouse model to study the HIV-1 antisense protein ASP
批准号:
10547001
负责人:
Fabio Romerio
金额:
$8.19万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
已结题
起止时间:
2022-08-12 至 2024-07-31
关键词:
Amino AcidsAnatomyBehavioralCD4 Positive T LymphocytesCell NucleusCell physiologyCell surfaceCellsCellular MembraneCharacteristicsClinicalDevelopmentFutureGenomeGoalsHIVHIV Envelope Protein gp120HIV-1HIV-2HumanHydrophobicityImmune responseImmunologicsIn VitroInfectionKnock-outKnowledgeLeadLong Terminal RepeatsLymphoidMorphologyMyelogenousNormal CellOpen Reading FramesPathogenesisPathologyPersonsPhenotypePlayPrevalencePrimate LentivirusesProteinsResearchRoleSIVSeriesTestingTransgenic MiceTransgenic ModelViralVirionVirusVirus Replicationcell envelopeenv Genesexperimental studyin vivoinducible gene expressionmouse modelnonhuman primatenovel therapeutic interventionpandemic diseasepromoterprotein expressiontool
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY
The negative strand of the HIV-1 proviral genome contains a highly conserved open reading frame (ORF) that
overlaps the env gene straddling the gp120/gp41 boundary. This ORF encodes an antisense protein (ASP) of
~189 residues, rich in hydrophobic amino acids, and associated with cellular membranes. Expression of ASP is
driven by a Tat-independent negative sense promoter (NSP) located in the 3’ long terminal repeat (LTR). The
presence of humoral and cellular immune responses against the ASP protein in people living with HIV-1 (PLWH)
provide evidence that ASP is expressed during HIV-1 infection in vivo.
The ASP ORF is found exclusively in HIV-1 strains that belong to clades of the pandemic group M, and the
percentage of strains in each clade that have an intact ASP ORF correlates with the worldwide prevalence of
the clade. On the contrary, the ASP ORF is absent in all other human and non-human primate lentiviruses: the
non-pandemic HIV-1 strains in groups O, N and P, HIV-2 strains, and SIV strains of all species. This suggests a
possible accessory role of ASP in virus spread. Indeed, our studies have shown that ASP is expressed in the
nucleus of non-productively infected cells, and on the cell surface of productively infected cells. In addition, upon
viral budding and release, ASP is present on the envelope of cell-free HIV-1 virions. We also found that knocking
out ASP expression reduces HIV-1 replication both in lymphoid and myeloid primary human cells. However,
despite mounting evidence that ASP is expressed in vivo, and that it promotes viral replication, the function and
the mechanism of action of ASP in HIV-1 infection and pathogenesis remain unknown.
The elucidation of the role that HIV-1 proteins play in viral replication, in promoting HIV-associated pathologies,
and in altering normal cell physiology has often relied on the development of transgenic (Tg) mouse models. The
central hypothesis of this application is that development of an ASP Tg mouse model will facilitate the study of
the function that ASP plays in the virus lifecycle, it will further advance our knowledge of HIV-1, and it may lead
to novel therapeutic interventions. We propose two specific aims. Specific Aim 1 seeks to establish a Tg mouse
model to study 3’LTR-driven, inducible expression of ASP in CD4+ cells, the natural targets of HIV-1 infection.
We have developed a construct that will allow us to achieve those goals, and we have performed in vitro exper-
iments to test its function. In addition to establishing the Tg model, this Specific Aim will confirm that ASP is
expressed in CD4+ cells in vivo after induction. Specific Aim 2 seeks to identify the main phenotypic character-
istics of ASP Tg mice. Under this Specific Aim, we will conduct a series of morphologic, anatomical, clinical,
behavioral, and immunological analyses that will allow us to fully characterize this new Tg mouse model and to
identify any pathologies or abnormalities.
At the conclusion of these studies, we will have established and characterized a new research tool that in future
studies will be used to test new hypotheses about the role of ASP in HIV-1 replication, spread, and pathogenesis.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
An inducible and cell specific transgenic mouse model to study the HIV-1 antisense protein ASP
-
批准号:10683237
-
项目类别:
-
资助金额:$8.19万
-
财政年份:2022
-
负责人:Fabio Romerio
-
依托单位:
Sustained HIV Remission via Sequence-Specific Epigenetic Silencing of Latent Proviruses
-
批准号:9751599
-
项目类别:
-
资助金额:$84.19万
-
财政年份:2019
-
负责人:Fabio Romerio
-
依托单位:
Sustained HIV Remission via Sequence-Specific Epigenetic Silencing of Latent Proviruses
-
批准号:10465271
-
项目类别:
-
资助金额:$63.16万
-
财政年份:2019
-
负责人:Fabio Romerio
-
依托单位:
Sustained HIV Remission via Sequence-Specific Epigenetic Silencing of Latent Proviruses
-
批准号:10327127
-
项目类别:
-
资助金额:$67.82万
-
财政年份:2019
-
负责人:Fabio Romerio
-
依托单位:
Sustained HIV Remission via Sequence-Specific Epigenetic Silencing of Latent Proviruses
-
批准号:9889884
-
项目类别:
-
资助金额:$84.77万
-
财政年份:2019
-
负责人:Fabio Romerio
-
依托单位:
Defining the HLA ligandome of HIV-1 latently infected CD4 + T cells
-
批准号:9408108
-
项目类别:
-
资助金额:$23.18万
-
财政年份:2017
-
负责人:Fabio Romerio
-
依托单位:
PrimeFlow RNA for detection of latently-infected CD4+ T cells
-
批准号:9300856
-
项目类别:
-
资助金额:$22.0万
-
财政年份:2016
-
负责人:Fabio Romerio
-
依托单位:
PrimeFlow RNA for detection of latently-infected CD4+ T cells
-
批准号:9137856
-
项目类别:
-
资助金额:$26.25万
-
财政年份:2016
-
负责人:Fabio Romerio
-
依托单位:
Cell Surface Marker Combinations to Identify Latently Infected CD4+ Cells In Vivo
-
批准号:8542182
-
项目类别:
-
资助金额:$25.3万
-
财政年份:2013
-
负责人:Fabio Romerio
-
依托单位:
Cell Surface Marker Combinations to Identify Latently Infected CD4+ Cells In Vivo
-
批准号:8719846
-
项目类别:
-
资助金额:$40.03万
-
财政年份:2013
-
负责人:Fabio Romerio
-
依托单位:
A New Insight into HIV-1 Latency Through a Novel in Vitro System
-
批准号:7895752
-
项目类别:
-
资助金额:$19.18万
-
财政年份:2009
-
负责人:Fabio Romerio
-
依托单位:
A New Insight into HIV-1 Latency Through a Novel in Vitro System
-
批准号:7756470
-
项目类别:
-
资助金额:$22.93万
-
财政年份:2009
-
负责人:Fabio Romerio
-
依托单位:
海外基金